<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871647</url>
  </required_header>
  <id_info>
    <org_study_id>PhD 53</org_study_id>
    <nct_id>NCT03871647</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After CABG</brief_title>
  <official_title>Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After Coronory Artery Bypass Grafting (CABG) Surgery in Egyptian Patients Receiving Beta Blockers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative Atrial Fibrillation (POAF) is one of the most common complications following&#xD;
      coronary artery bypass grafting (CABG) occurring to 20% - 40% of patients. It is associated&#xD;
      with prolonged hospitalization, increased hospital costs, increased complications and&#xD;
      mortality rate.&#xD;
&#xD;
      Despite the use of Beta Blockers, approximately 20% of patients develop atrial fibrillation&#xD;
      following CABG surgery, suggesting a role for polymorphism in the genes The aim of the&#xD;
      present study is to determine the minor allele frequency of some of the genes that affect the&#xD;
      beta blockers' response and to determine the association between polymorphism in these genes&#xD;
      and the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting&#xD;
      in Egyptian patients receiving perioperative beta blockers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">March 7, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Atrial fibrillation</measure>
    <time_frame>within 6 days after the operation</time_frame>
    <description>Atrial fibrillation based on postoperative electrocardiogram. AF diagnostic criteria will include absence of discrete P waves, the RR intervals follow unrepetitive form and the ranges of ventricular rate usually between 90 and 170 beats/min.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">256</enrollment>
  <condition>Coronary Bypass Graft Surgery</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>POAF group</arm_group_label>
    <description>Patients who will experience AF at any time during the first six days after the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non POAF group</arm_group_label>
    <description>Patients with a sinus rhythm during the first six days after the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker</intervention_name>
    <description>perioperative beta blockers</description>
    <arm_group_label>Non POAF group</arm_group_label>
    <arm_group_label>POAF group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Egyptian patients undergoing Coronary Artery Bypass grafting Surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age above 18 years.&#xD;
&#xD;
          2. Candidates for CABG surgery without a concurrent valve surgery.&#xD;
&#xD;
          3. Patients receiving perioperative beta blockers before new onset of postoperative AF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have either persistent or permanent AF, atrial flutter or atrial&#xD;
             tachycardia on ECG obtained on the day of the operation.&#xD;
&#xD;
          2. Serum creatinine &gt;2 mg/dL before the surgery.&#xD;
&#xD;
          3. Uncontrolled thyroid disease.&#xD;
&#xD;
          4. Recent treatment with amiodarone before the occurrence of POAF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina M El Gindy, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr Ineternational University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lamiaa M ElWakeel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona F Schaalan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramy MR Khorshid, Md, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams Uiversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed H Solayman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Sham University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cardiovascular &amp; Thoracic Academy - Ain Shams University.</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr International University</investigator_affiliation>
    <investigator_full_name>Dina Mohamed Kamal El gindy</investigator_full_name>
    <investigator_title>Assistant Lecturer of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

